Developing growth hormone products since 1985
Genentech continues to be at the forefront in developing innovative products for patients who may benefit from recombinant human growth hormone (hGH or GH). Our products are approved for a range of indications and clearly demonstrate Genentech's commitment to the endocrinology community. The Nutropin family of products allows for customized solutions and options to meet the needs of your growth hormone patients.
Nutropin AQ Pen 20 for use with the Nutropin AQ Pen 20mg Cartridge, Nutropin AQ Pen 10 for use with the Nutropin AQ Pen 10mg Cartridge, Nutropin AQ and Nutropin are indicated for the long-term treatment of idiopathic short stature, also called non-growth hormone-deficient short stature, defined by height SDS <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range, in pediatric patients whose epiphyses are not closed and for whom diagnostic evaluation excludes other causes associated with short stature that should be observed or treated by other means.
The Nutropin AQ Pen is available in the United States by prescription only. The Nutropin AQ Pen is intended for use with the Nutropin AQ Pen cartridge. Patients should not use the Nutropin AQ Pen until instructed in its use by their healthcare provider.
Nutropin AQ, the first GH in liquid formulation, was designed to simplify preparation by eliminating reconstitution. It has been approved for the treatment of children with growth failure due to a lack of adequate endogenous GH secretion (GHD), of growth failure associated with chronic renal insufficiency (CRI) up to the time of renal transplantation, and of short stature associated with Turner syndrome. It is also indicated for the replacement of endogenous GH in patients with diagnosed adult GH deficiency (AGHD).*
Nutropin was approved by the FDA in 1993. It is available for the long-term treatment of growth failure due to a lack of adequate endogenous GH secretion, and of growth failure associated with chronic renal insufficiency (up to the time of renal transplantation). Nutropin is also approved for the treatment of short stature associated with Turner syndrome, and for the replacement of endogenous GH in adult patients who have been biochemically diagnosed with adult GH deficiency.*
Protropin® (somatrem for injection), approved by the FDA in 1985, was the first recombinant GH product for GH deficiency. It was phased out at the end of 2004.
*Nutropin and Nutropin AQ are indicated for the replacement of endogenous GH in patients with adult GH deficiency (AGHD) who meet either of the following two criteria:
- Biochemical diagnosis of AGHD by means of a subnormal response to a standard GH stimulation test (peak GH <5 μg/L), and
- Adult-onset: Patients who have AGHD either alone or with multiple hormone deficiencies (hypopituitarism) as a result of pituitary disease, hypothalamic disease, surgery, radiation therapy, or trauma; or
Childhood-onset: Patients who were GH-deficient during childhood, confirmed as an adult before replacement therapy with Nutropin or Nutropin AQ is started
